Item 8.01 Other Events.

On September 9, 2024, Hims & Hers Health, Inc. (the "Company") filed a prospectus supplement dated September 9, 2024 (the "Prospectus Supplement"), which forms part of the Company's automatic "shelf" Registration Statement on Form S-3 (File No. 333-282008), which was filed on September 9, 2024 with the Securities and Exchange Commission. The Prospectus Supplement supplements the base prospectus contained in the Registration Statement, and was filed to register 976,341 shares of the Company's Class A common stock (the "Resale Shares") issued to Nivagen Pharmaceuticals, Inc. ("Nivagen") in connection with the acquisition by the Company (the "Medisource Acquisition") of 100% of the membership interests of Seaview Enterprises LLC (d/b/a MedisourceRx) ("Medisource") pursuant to the purchase agreement dated July 5, 2024, by and among the Company, Nivagen, and Medisource (the "Purchase Agreement"). The Medisource Acquisition closed on September 5, 2024.

The offering of the Resale Shares was made pursuant to an exemption from registration under the Securities Act of 1933, as amended (the "Securities Act"). The Prospectus Supplement was filed in accordance with the Purchase Agreement.

A copy of the opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP relating to the legality of the Resale Shares is filed herewith as Exhibit 5.1.